| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| InflaRx N.V. | Vilobelimab (IFX-1) - (IXPLORE) | ANCA-associated vasculitis (AAV) | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| InflaRx N.V. | Vilobelimab (IFX-1) | Cutaneous squamous cell carcinoma (cSCC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| InflaRx N.V. | Vilobelimab (IFX-1) - (IXPLORE) | ANCA-associated vasculitis (AAV) | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| InflaRx N.V. | Gohibic (vilobelimab) - (PANAMO) | COVID-19 | Phase 3 | Data Released | Intravenous | COVID-19 |
| InflaRx N.V. | Vilobelimab (IFX-1) | Pyoderma Gangrenosum (PG) | Phase 3 | Trial Discontinued | Intravenous | Immunology |
| InflaRx N.V. | Vilobelimab (IFX-1) - (IXCHANGE) | ANCA-associated Vasculitis (AAV) | Phase 2 | Data Released | Intravenous | Immunology |
| InflaRx N.V. | Vilobelimab (IFX-1) | Hidradenitis Suppurativa | Phase 2 | Trial Completed | Intravenous | Immunology: Anti-TNF |
| InflaRx N.V. | Izicopan (INF904) | Chronic Autoimmune and Inflammatory Diseases | Phase 2a | Data Released | Oral | Immunology |